Medical/Pharmaceuticals
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealand * In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via...
2021-06-02 06:00
1870
Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeting
BEIJING and BOSTON, June 1, 2021 /PRNewswire/ -- Eucure Biopharma will present findings from two Phase I clinical trials at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held fromJune 4th to 8th. The first trial (poster #2580; NCT04481009) is designed to assess the safety...
2021-06-02 01:28
1792
New 3M™ Harvest RC clarifier brings chromatography technology to harvest clarification with a single-stage solution for upstream processes
ST. PAUL, Minn., June 2, 2021 /PRNewswire/ -- 3M Health Care launched 3M™ Harvest RC clarifier, leveraging its proprietary fibrous chromatography media to deliver a single-stage purification solution for recombinant protein therapeutic manufacturing. It is the next generation in harvest and clar...
2021-06-02 01:00
6124
Puyi Biotechnology Completes Series B Financing
SHANGHAI, June 1, 2021 /PRNewswire/ -- Puyi (Shanghai) Biotechnology Co., Ltd. ("Puyi Biotechnology") recently announced the completion of its Series B financing led by Goldman Sachs Asset Management. The proceeds will be used to further augment R&D and business development. Puyi Biotechnology i...
2021-06-01 22:32
3419
Daewoong Pharmaceutical Publishes Results of First Clinical Study of SGLT-2 Inhibitor 'Enavogliflozin' for Canine Diabetes
SEOUL, South Korea, June 1, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (CEO Sengho Jeon) announced that the results of an investigator-initiated clinical study on the effect of Enavogliflozin, originally developed as Type II Diabetes Treatment forhumans, on treating canine diabetes were publish...
2021-06-01 21:00
2034
GenScript ProBio and Neoletix signed a letter of intent on clinical and commercial production of recombinant human coagulation factor VIII
NANJING, China, June 1, 2021 /PRNewswire/ -- On June 1st 2021, GenScript ProBio and Neoletix (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as Neoletix) signed a letter of intent on cooperation for clinical and commercial production of human coagulation factor VIII. GenScript ProBio s...
2021-06-01 21:00
1694
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study
VANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF)("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Prac...
2021-06-01 20:00
4662
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for the Treatment of Ocular Diseases
HOUSTON and SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-mediated gene therapies for the treatment of ocular diseases, and Hopstem Biotechnology, the leading human induced pluripotent stem cell (hiPSC) and neural...
2021-06-01 19:50
1504
Occlutech takes important step towards approval in China
SCHAFFHAUSEN, Switzerland, June 1, 2021 /PRNewswire/ -- Occlutech AG ("Occlutech" or the "Company") today announces that the planned recruitment of 180 patients has been reached in the Company's trial inChina for its ASD Occluder. The Occlutech ASD Occluder is used in the treatment of Atrial Sept...
2021-06-01 19:02
2348
Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials
Highlights: * Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman andPitt Hopkins syndromes * Positive outcome is an important milestone that enables Neuren to proceed with IND...
2021-06-01 18:00
1487
Scripps Research Institute testing shows Viraleze highly active against UK COVID strain
MELBOURNE, Australia, June 1, 2021 /PRNewswire/ -- Australia's Viraleze anti-COVID nasal spray is active against the highly infectious UK variant of SARS-CoV-2, the virus that causes COVID-19, reducing infectivity of the virus by >98%, it was announced today in a major development for the product...
2021-06-01 17:30
1925
Australia's original prolonged-release melatonin now available over the counter at pharmacies
MAIN POINTS * Circadin® prolonged-release melatonin is now available without prescription1 * Circadin® is clinically proven in people aged 55 and over2 to help them fall asleep quicker, sleep better, wake refreshed, and in turn improve quality of life3 * Circadin® mimics the effect of the b...
2021-06-01 17:05
2130
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Agreement Renews Successful Global Collaboration That led to Several Groundbreaking Therapies in Multiple Disease Areas KHK4083 Depletes OX40-Expressing T cells Associated with Atopic Dermatitis and Several Other Inflammatory Diseases Moderate-to-Severe Atopic Dermatitis Affects Nearly 30 Mill...
2021-06-01 16:00
5391
100th Elekta Unity MR-Linac goes to St George's Hospital in New Zealand
CHRISTCHURCH, New Zealand, June 1, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announces that St George's Hospital inChristchurch, New Zealand, has ordered an Elekta Unity MR-Linac, making it the 100th device sold since introduction. Today, the innovative radiation therapy device is found in 14 count...
2021-06-01 15:07
5001
AVATAMED sets up Joint Service Lab with A*STAR's Institute of Molecular and Cell Biology to offer Precision Oncology Services
SINGAPORE, June 1, 2021 /PRNewswire/ -- AVATAMED (www.avatamed.com
2021-06-01 09:00
2628
Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China
SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-06-01 08:00
4958
Introduce the World's First Biomedical Application Mask that Revolutionizes Face Mask to Resist Aerosol Transmission
TAIPEI, May 31, 2021 /PRNewswire/ -- Taer Innovation has won design awards including Good Design award from 2012 to 2014 Golden Pin Design award, Taiwan Excellence award in 2014 and Computex d&I award in 2014 for their products.The companyfocuses on medical innovation and technology. The company'...
2021-05-31 23:00
2152
PENTAX Medical and Vedkang Establish Endoscopic Therapeutics Joint Venture
TOKYO, May 31, 2021 /PRNewswire/ -- PENTAX Medical (a division of HOYA Group) and Jiangsu Vedkang Medical Science and Technology Co., Ltd (Vedkang) today announced the establishment of a joint venture- PENTAX Medical Therapeutics ( Jiangsu) Co., Ltd.(*) to develop single-use therapeutics products ...
2021-05-31 21:00
2808
PolyU develops biomimetic nanosheet for cancer therapy and imaging
HONG KONG, May 31, 2021 /PRNewswire/ -- A research team from the Department of Applied Biology and Chemical Technology (ABCT) of The Hong Kong Polytechnic University (PolyU) has developed a novel type of biomimetic nanosheet with a multi-modal imaging function, which can track tumour development ...
2021-05-31 19:42
2906
RhoVac Confirms Forecast - BRaVac Phase IIb study recruitment to close in Quarter 3 2021
STOCKHOLM, May 31, 2021 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today,May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021. Also, all new US clinics hav...
2021-05-31 19:33
2033
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Novo Nordisk International Operations Commits to Veeva Vault CRM
[Picked up by 287 media titles]
2026-01-08 09:05Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 282 media titles]
2026-01-07 10:00
Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026
[Picked up by 282 media titles]
2026-01-08 12:01
Most Read
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7886
The Greatest Meeting The Greatest: Roborock joins hands with Real Madrid in strategic partnership with innovation at the core
2026-01-02 19:00
7436
